Small cap: ReNeuron directors buy shares
Directors buy shares in company developing innovative stem cell therapies
Two directors at small cap ReNeuron bought shares in the company on January 29 worth a total of around £15,000.
Olav Hellenbo, chief executive officer, purchased for the first time, buying 322,778 shares at a price of 3.1p to take a 0.02% stake. Michael Hunt, chief financial officer bought 161,556 shares to increase his stake to 0.08%.
The clinical-stage cell therapy development company has begun a Phase II clinical trial aimed at developing treatments for those suffering from stroke disability.
Neil Woodford, manager of the CF Woodford Equity Income Fund, increased his stake in ReNeuron to 20.05%, earlier this month.
The writer holds shares in ReNeuron